Cancer Therapy Lab
A dedicated facility for Electro-Capacitive Cancer Therapy. Clinical protocol, patient intake, monitoring through ECVT imaging, and follow-up — all under one roof. Low-level capacitive fields. No radiation. No systemic toxicity.
A complete clinical pathway for capacitive cancer therapy.
The Cancer Therapy Lab supports patients receiving Electro-Capacitive Cancer Therapy — from initial assessment through active treatment to monitoring and follow-up. The lab operates the full clinical ECCT protocol established following ethical clearance in 2012 and refined across more than 5,000 patient cases.
ECCT delivers low-frequency (below 300 kHz), low-intensity (below 30 Vpp) capacitive fields through body-conforming electrode garments. The physical mechanism — selective disruption of the mitotic spindle in rapidly dividing cancer cells — produces no radiation, no systemic toxicity, and no requirement for hospital admission during active therapy. The Cancer Therapy Lab administers the treatment protocol, monitors patient response through ECVT imaging, and coordinates with clinical oncology partners for integrated care.
The lab also supports patients who use ECCT alongside conventional treatments — the approximately 37% of cases in the clinical population who combine ECCT with ongoing chemotherapy, radiotherapy, or surgical programmes — and patients who come to ECCT after exhausting other options.
From intake to monitoring — the clinical pathway.
Where the lab's clinical record is established.
Based on the published clinical research and the patient cohort treated since ethical clearance in 2012.
Glioblastoma & Brain Tumours
ECCT delivered via helmet garment. For inoperable tumours — particularly soft, highly polarised types in the interbrain and midbrain — ECCT offers an option where surgery is unavailable. ECVT brain imaging monitors intracranial response.
Breast Cancer
Reduced proliferation in MCF-7 breast cancer cell lines confirmed in vitro. Wearable garment for home delivery. ECVT breast scanner provides radiation-free permittivity mapping for treatment monitoring alongside mammography.
Lung Cancer
A case series presented at GLOBEHEAL 2026 (Prof. Shinichiro Akayama) reported substantially longer survival in advanced-stage lung cancer patients using ECCT alongside standard therapy. Adenocarcinomas — soft and highly polarised — respond well; findings await confirmation in larger independent trials.
Liver Cancer
Small metastatic lesions not applicable for surgery respond well to ECCT — dead cells discharge through nearby ducts and veins. The lab manages treatment protocols for liver primary and metastatic disease.
Cervical Cancer
Conforming electrode garments adapted to anatomical site. Clinical programme covering cervical cancer populations, coordinated with oncology partners for integrated care alongside conventional treatment.
Metastatic Disease
Blanket-style garment for whole-body ECCT in metastatic disease. For patients with bone, liver, lung, and brain spread — particularly those who have exhausted conventional options (approximately 57% of the clinical population).
.jpg)
What the evidence supports.
The ECCT clinical programme began in 2010. Ethical clearance was granted in 2012. The programme reports treatment across more than 5,000 patients spanning glioblastoma, breast, lung, liver, and cervical cancers — treated in Indonesia and in international clinical research collaborations in Japan (Prof. Shinichiro Akayama) and through oncology partnerships (Dr. B. Kaplan). These figures come from clinical case records and conference presentations rather than independent, peer-reviewed, large-scale trials, and Indonesian health authorities have stated that ECCT's safety and efficacy require further evidence.
The physical selectivity mechanism — electrically charged protein structures forming the mitotic spindle interact with sub-300 kHz fields in ways determined by the cell's membrane potential and division rate; cancer cells, dividing faster with altered membrane potentials, are preferentially disrupted — was established in biophysics research (Abdulhakim Coskun, Biophysicist, Georgia Institute of Technology). In vitro and in vivo studies confirmed reduced MCF-7 proliferation and inhibited tumour growth in murine models, with cytokine changes indicating immune microenvironment modulation.